Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scanner could replace dye injections for retinal disease

NCT ID NCT03279939

Diagnosis Sponsor: Heidelberg Engineering GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new imaging device called OCT angiography (OCTA) that takes 3D pictures of blood vessels in the back of the eye without needing dye injections. Researchers compared OCTA images to standard dye-based imaging in 88 people with retinal blood vessel problems or normal eyes. The goal was to see if OCTA provides good image quality and shows clinically useful details.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this imaging method could replace dye-based tests, making eye exams faster and safer for patients with retinal conditions.
What could go wrong
This is a small, completed study focused on image quality, not treatment. The device may not be better than existing methods for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

88 people

The number who actually took part.

Started

Aug 2017

Finished

Jan 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with Normal Eyes: * Subjects presenting at the site without uncontrolled systemic conditions, or ocular disease, as determined by the Investigator * Corrected visual acuity ≥ 20/40 in each eye * No history of ocular surgical intervention (except for refractive or cataract surgery) in either eye Subjects with Pathology: * Subjects with retinal conditions in at least one eye. * Subjects included can have a range of retinal vascular pathologies affecting different anatomic depths through the retina and choroid. Retinal conditions including but not limited to diabetic retinopathy, wet age-related macular degeneration (AMD), and branch or central retinal vein occlusion that give rise to features such as retinal ischemia, microaneurysms, choroidal neovascularization and retinal neovascularization will be included.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All subjects: * Able and willing to undergo the test procedures, sign informed consent, and follow instructions. * Age ≥ 22 Subjects with Normal Eyes: * Subjects presenting at the site without uncontrolled systemic conditions, or ocular disease, as determined by the Investigator * Corrected visual acuity ≥ 20/40 in each eye * No history of ocular surgical intervention (except for refractive or cataract surgery) in either eye Subjects with Pathology: * Subjects with retinal conditions in at least one eye. * Subjects included can have a range of retinal vascular pathologies affecting different anatomic depths through the retina and choroid. Retinal conditions including but not limited to diabetic retinopathy, wet age-related macular degeneration (AMD), and branch or central retinal vein occlusion that give rise to features such as retinal ischemia, microaneurysms, choroidal neovascularization and retinal neovascularization will be included. Exclusion Criteria: * Subjects unable to read or write * Subjects with ocular media not sufficiently clear to obtain acceptable study-related imaging * Subjects who cannot tolerate the imaging procedures * Subjects with known allergies to fluorescein dye, Indocyanine Green (ICG), shellfish, drugs for pupillary dilation * Subjects with contraindication to pupillary dilation in study eye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Branch retinal vein occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

branch retinal artery occlusion central retinal vein occlusion diabetic retinopathy retinal vascular disorder wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Normal eyes Retinal vascular

Contacts and locations

Locations

  • Retina Consultants of Houston

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.